Body Pharm Semax 10

Researchers looking to buy Semax 10mg in South Africa can source the Body Pharm-branded vial domestically, avoiding the 4-to-6 week import lag and customs queries that typically accompany Eastern European peptide orders. Semax is a synthetic heptapeptide (MEHFPGP, C39H54N10O10, MW ~811.9 g/mol, CAS 80714-61-0) derived from the ACTH(4–10) fragment with a Pro-Gly-Pro C-terminal extension. Research in rat focal-ischaemia models has documented BDNF upregulation and neuroprotective signalling; the Pro-Gly-Pro extension confers enzymatic stability and extends central nervous system bioavailability.

This page consolidates what South African procurement officers need: ZAR pricing context, shipping logistics within the Republic, the current SAHPRA grey-area status for ACTH-fragment research peptides, and a citation-ready mechanistic summary so the vial on your bench arrives with its pharmacology already documented. Last updated: 2026.

Key Takeaways

• Body Pharm Semax 10 mg is a lyophilised research-grade heptapeptide (MEHFPGP) available locally at approximately R1,200–R1,600 per vial
• The peptide upregulates BDNF and TrkB receptor signalling in rodent models, with documented effects in ischaemia recovery and cognition endpoints
• SAHPRA has issued no specific 2024–2026 guidance on short ACTH-fragment peptides; procurement for in vitro and preclinical research remains permissible under existing frameworks
• Storage at −20 °C in sealed, desiccated conditions preserves peptide integrity; reconstituted solutions degrade within 28 days at 4 °C
• Semax differs from Selank in primary research endpoint: Semax targets BDNF-linked neuroprotection, while Selank targets anxiolytic and immune-modulation pathways

What Is Body Pharm Semax 10 mg?

Body Pharm Semax 10 mg is a lyophilised research-grade vial containing 10 mg of the synthetic heptapeptide Semax (sequence Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP). It is a synthetic analogue of the ACTH(4–10) fragment with a C-terminal Pro-Gly-Pro extension. This tripeptide tail blocks aminopeptidase and carboxypeptidase cleavage, conferring enzymatic stability. The vial ships as a white-to-off-white powder intended for reconstitution in bacteriostatic water or sterile saline at the researcher's chosen concentration.

The peptide carries molecular formula C39H54N10O10 and a molecular weight of approximately 811.9 g/mol, with CAS 80714-61-0 consistently assigned across primary chemical databases into 2025–2026. Body Pharm positions the product as research-use-only material, consistent with how other Body Pharm peptides are distributed through South African resellers.

Store lyophilised Semax at −20 °C in a desiccated, light-protected environment to preserve sequence integrity over the vial's shelf life. Peptide bonds hydrolyse at higher temperatures and in the presence of moisture. Researchers comparing closely related ACTH-derived nootropics may also want to review the Selank research peptide entry alongside the broader Semax peptide overview.

Semax Mechanism of Action: BDNF and ACTH Signalling

Semax exerts its neuroprotective effects primarily through upregulation of brain-derived neurotrophic factor (BDNF) and its TrkB receptor in hippocampal tissue. Semax originates as a stabilised ACTH(4–10) fragment that retains melanocortin-like CNS activity without the steroidogenic action of full-length ACTH. The parent sequence corresponds to residues 4–10 of the adrenocorticotropic hormone precursor (UniProt P01189). The C-terminal Pro-Gly-Pro extension in MEHFPGP sterically blocks aminopeptidase and carboxypeptidase cleavage, extending plasma and cerebrospinal fluid (CSF) half-life sufficiently for intranasal dosing to produce measurable central effects.

BDNF and TrkB upregulation

Rodent ischaemia work by Gubsky and colleagues documented Semax-driven changes in neurotrophin- and plasticity-related gene expression in rat brain. Following 50–150 µg/kg intranasal administration, downstream increases in BDNF transcript and TrkB (NTRK2) receptor signalling were reported across the hippocampus and cortex. These transcriptional shifts are the most consistently replicated molecular signature of Semax in preclinical models to date, and they remain the basis for its classification as a neurotrophin-modulating peptide in 2026 review literature.

Monoaminergic modulation

A secondary pathway involves modulation of serotonergic and dopaminergic tone in rodent striatum and limbic regions, which contributes to the anxiolytic and attentional effects reported alongside the neuroprotective profile. The precise high-affinity receptor target in humans has not been definitively identified as of 2026. Mechanistic discussion still leans on pre-2020 Russian and Eastern European preclinical work; no Phase III human trials outside the Russian Federation have been published in indexed literature. Researchers comparing mechanisms across short regulatory peptides may find the Selank research peptide entry a useful cross-reference.

Research Applications Investigated in Preclinical Models

Semax has been investigated across three main preclinical endpoint clusters: ischaemic neuroprotection, rodent cognition, and stress-related anxiolytic-adjacent behaviour. All cited data derive from in vitro or animal work. No Phase III human trial outside the Russian Federation has been published in indexed literature as of 2026.

Ischaemia and reperfusion models

The Gubsky 2014 rat focal ischaemia work remains the most-cited mechanistic dataset, reporting Semax-driven shifts in vascular and neuroplasticity gene expression after intranasal dosing in the 50–150 µg/kg range. No South African university or CSIR group has published indexed Semax ischaemia work in the 2020–2026 window. Protocols designed locally still rely on Russian and Eastern European source data.

Cognition and memory endpoints

Rodent cognition studies have used Morris water maze and novel object recognition paradigms to probe Semax effects on spatial learning and recognition memory. Effects are attributed to the BDNF/TrkB upregulation discussed earlier, as these assays measure hippocampal-dependent learning. The 2026 Innerbody review summarises these as neuroprotective effects without citing fresh 2024–2025 primary rodent data, worth flagging for protocol design.

Stress and regulatory context

Stress-model work has examined anxiolytic-adjacent endpoints linked to monoaminergic modulation. Semax is registered in the Russian Federation as a nasal spray for clinical use. SAHPRA has issued no equivalent registration or specific guidance on ACTH-fragment research peptides, so local procurement sits in a case-by-case grey area under existing medicines frameworks. For comparative neuropeptide context, see the Semax peptide overview and the Selank research peptide entries.

Semax vs Selank: A Quick Research Comparison (2026)

Semax and Selank are both short regulatory peptides derived from endogenous Russian-developed templates, but they target different research endpoints. Semax (MEHFPGP) is an ACTH(4–10) analogue used primarily for BDNF-linked neuroprotection and cognition work. Selank (TKPRPGP) is a tuftsin analogue used primarily for anxiolytic and immune-modulation endpoints. Their parent sequences activate distinct receptor pathways.

Parameter	Semax	Selank
Sequence	MEHFPGP (heptapeptide)	TKPRPGP (heptapeptide)
Origin fragment	ACTH(4–10) + Pro-Gly-Pro	Tuftsin (TKPR) + Pro-Gly-Pro
Primary research endpoint	BDNF upregulation, neuroprotection, ischaemia recovery	Anxiolytic signal, immune modulation
BDNF effect	Documented upregulation in rat focal ischaemia models	Indirect/weaker signal in indexed literature
Anxiolytic signal	Secondary, monoaminergic-linked	Primary endpoint
Typical rodent dose range	50–150 µg/kg intranasal	100–300 µg/kg intranasal
Stability	Lyophilised powder, −20 °C; reconstituted aliquots short-lived	Comparable handling profile

Both are stocked locally as 10 mg lyophilised vials. Choose Semax when the protocol targets neurotrophin signalling, post-ischaemic plasticity, or cognition endpoints. Choose Selank when the design centres on anxiety models or cytokine readouts. For category context, see the Semax peptide overview.

Buying Body Pharm Semax 10 mg in South Africa

Body Pharm Semax 10 mg is stocked locally as a lyophilised vial for research use only. Indicative pricing falls in the R1,200–R1,600 range per 10 mg vial (confirm the current ZAR figure at checkout, as published 2026 retail figures for this specific SKU were not independently verifiable at the time of writing). There is no minimum order; single-vial purchases are accepted for laboratory procurement.

Checkout accepts South African EFT, Ozow instant EFT, and major card payments. Orders dispatch via tracked, discreet courier, typically Aramex, Courier Guy, or PostNet-to-PostNet, with 2–4 business day delivery to major metros and 3–6 business days to outlying areas. Lyophilised Semax ships ambient when sealed. On receipt, store at −20 °C and reconstitute only working aliquots. The MEHFPGP heptapeptide (MW ~811.9 g/mol, CAS 80714-61-0) degrades in solution due to hydrolysis and microbial contamination.

Material is supplied strictly for in vitro and preclinical research. SAHPRA has issued no specific 2024–2026 guidance on short ACTH-fragment peptides, so end-users carry responsibility for compliant handling. Browse the full Semax peptide overview or compare with Selank research peptide before ordering.

Regulatory Status in South Africa (SAHPRA)

Semax is not registered as a Schedule medicine with SAHPRA. No specific entry for the MEHFPGP heptapeptide appears in publicly available 2024–2025 SAHPRA scheduling notices. It is supplied locally as a research chemical, meaning procurement is permissible for in vitro and preclinical laboratory work. The material is not authorised for human consumption, clinical administration, or any therapeutic claim; SAHPRA requires all medicines intended for human use to undergo formal registration.

The governing framework is the Medicines and Related Substances Act 101 of 1965 (as amended). Under this Act, any peptide marketed with therapeutic indications requires registration as a medicine. SAHPRA communications through 2024–2025 have reiterated that position without naming short ACTH-derived fragments specifically. Semax therefore sits in a research-use grey area that must be interpreted case-by-case, as regulatory precedent for this specific peptide class has not been formally established.

Before any study involving biological samples, animal models, or human-derived tissue, clear use through your institutional research ethics committee. This article is not legal advice. For specific procurement or scheduling queries, consult a qualified regulatory consultant. Researchers comparing analogues may also review the Selank research peptide page for parallel context.

Storage and Handling for Research Integrity

Store lyophilised Semax at −20 °C in its sealed vial, protected from light and moisture. Peptide bonds are susceptible to hydrolysis and oxidation. Under these conditions, dry heptapeptide stock typically remains stable for the duration of standard research timelines, provided the seal is intact.

Reconstitute with bacteriostatic water or sterile 0.9% saline, calculating volume against your intended working concentration. For example, 2 mL into a 10 mg vial yields 5 mg/mL. Once reconstituted, hold the solution at 4 °C and use within 28 days as standard peptide guidance. Defer to any divergent instructions on the Body Pharm Certificate of Analysis if supplied.

Minimising degradation in practice

Avoid repeated freeze-thaw cycles, which fragment the MEHFPGP backbone and reduce assayable potency. Ice crystal formation disrupts peptide structure. Aliquot the reconstituted stock into single-use volumes before refrigeration. For sterile in vitro work, handle reconstitution and aliquoting inside a Class II laminar flow hood. Researchers cross-referencing handling protocols for related ACTH-adjacent peptides can review the Selank research peptide page, or return to the Semax peptide overview for the parent category context.

Frequently Asked Questions